Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Histologically or cytologically documented, locally advanced or metastatic solid tumors or lymphoma for which standard therapy either does not exist or has proven ineffective or intolerable
Life expectancy greater than or equal to (\>=) 12 weeks, in the opinion of the investigator
Adequate hematologic, liver, and renal function
For Stage 2: Participants with human epidermal growth factor receptor 2 (HER2) negative, estrogen-receptor (ER) negative, and progesterone-receptor (PR) negative breast cancer
For Stage 2: Participants with non-mucinous, platinum-resistant ovarian cancer with documented radiographic progression or relapse according to RECIST within 6 months of receiving platinum-based chemotherapy
For Stage 2: Participants with histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer (NSCLC); mixed histology that is predominantly squamous is acceptable
You may not be if
History of prior significant toxicity from a same class of agents as GDC-0575 or gemcitabine requiring discontinuation of treatment
All acute toxicities related to prior therapy must have resolved prior to study entry, except for alopecia and mild neuropathy
Current severe, uncontrolled systemic disease (including but not limited to clinically significant cardiovascular, pulmonary, or renal disease or ongoing or active infection) excluding the cancer under study
History of significant cardiac dysfunction
History of malabsorption or other condition that would interfere with enteral absorption
Known human immunodeficiency virus (HIV) infection
Pregnancy, lactation or breastfeeding
Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms
Current use of alpha-adrenergic receptor blockers
For Combination Arm only:
Any contraindication to gemcitabine therapy
More than two regimens of cytotoxic chemotherapy for the treatment of locally advanced or metastatic cancer
History of receiving high-dose chemotherapy requiring bone marrow or stem cell support
Irradiation to more than 25% of bone marrow-bearing areas
Clareo Health | A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma
